The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity

被引:87
作者
Popescu, Iuliana Ristea [1 ,2 ,3 ,4 ]
Helleboid-Chapman, Audrey [1 ,2 ,3 ,4 ]
Lucas, Anthony [1 ,2 ,3 ,4 ]
Vandewalle, Brigitte [2 ,4 ,5 ]
Dumont, Julie [1 ,2 ,3 ,4 ]
Bouchaert, Emmanuel [1 ,2 ,3 ,4 ]
Derudas, Bruno [1 ,2 ,3 ,4 ]
Kerr-Conte, Julie [2 ,4 ,5 ]
Caron, Sandrine [1 ,2 ,3 ,4 ]
Pattou, Francois [2 ,4 ,5 ]
Staels, Bart [1 ,2 ,3 ,4 ]
机构
[1] Inst Pasteur, INSERM, UMR1011, F-59019 Lille, France
[2] Univ Lille Nord France, F-59000 Lille, France
[3] INSERM, UMR1011, F-59000 Lille, France
[4] UDSL, F-59000 Lille, France
[5] CHRU Lille, INSERM, U859, Lab Diabet Cell Therapy, F-59000 Lille, France
关键词
Farnesoid X receptor; Type; 2; diabetes; Islet; Lipotoxicity; FARNESOID-X-RECEPTOR; BILE-ACIDS; INSULIN SENSITIVITY; GLUCOSE; GENE; ACTIVATION; SECRETION; LIGANDS; MICE;
D O I
10.1016/j.febslet.2010.04.068
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Farnesoid X receptor (FXR) is highly expressed in liver and intestine where it controls bile acid (BA), lipid and glucose homeostasis. Here we show that FXR is expressed and functional, as assessed by target gene expression analysis, in human islets and beta-cell lines. FXR is predominantly cytosolic-localized in the islets of lean mice, but nuclear in obese mice. Compared to FXR+/+ mice, FXR-/- mice display a normal architecture and b-cell mass but the expression of certain islet-specific genes is altered. Moreover, glucose-stimulated insulin secretion (GSIS) is impaired in the islets of FXR-/- mice. Finally, FXR activation protects human islets from lipotoxicity and ameliorates their secretory index. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:2845 / 2851
页数:7
相关论文
共 29 条
[1]   Synergistic activation of the insulin gene promoter by the β-cell enriched transcription factors MafA, Beta2, and Pdx1 [J].
Aramata, S ;
Han, S ;
Yasuda, K ;
Kataoka, K .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2005, 1730 (01) :41-46
[2]   Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis [J].
Bhatnagar, Sushant ;
Damron, Holly A. ;
Hillgartner, F. Bradley .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (15) :10023-10033
[3]   The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice [J].
Cariou, B ;
van Harmelen, K ;
Duran-Sandoval, D ;
van Dijk, TH ;
Grefhorst, A ;
Abdelkarim, M ;
Caron, S ;
Torpier, G ;
Fruchart, JC ;
Gonzalez, FJ ;
Kuipers, F ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) :11039-11049
[4]   Nuclear hormone receptor expression in the endocrine pancreas [J].
Chuang, Jen-Chieh ;
Cha, Ji-Young ;
Garmey, James C. ;
Mirmira, Raghavendra G. ;
Repa, Joyce J. .
MOLECULAR ENDOCRINOLOGY, 2008, 22 (10) :2353-2363
[5]   Glucose regulates the expression of the farnesoid X receptor in liver [J].
Duran-Sandoval, D ;
Mautino, G ;
Martin, GV ;
Percevault, F ;
Barbier, O ;
Fruchart, JC ;
Kuipers, F ;
Staels, B .
DIABETES, 2004, 53 (04) :890-898
[6]   Attenuation of FGF signalling in mouse β-cells leads to diabetes [J].
Hart, AW ;
Baeza, N ;
Apelqvist, Å ;
Edlund, H .
NATURE, 2000, 408 (6814) :864-868
[7]   Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray [J].
Higashiyama, Hiroyuki ;
Kinoshita, Mine ;
Asano, Satoshi .
ACTA HISTOCHEMICA, 2008, 110 (01) :86-93
[8]   Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis [J].
Holt, JA ;
Luo, GZ ;
Billin, AN ;
Bisi, J ;
McNeill, YY ;
Kozarsky, KF ;
Donahee, M ;
Wang, DY ;
Mansfield, TA ;
Kliewer, SA ;
Goodwin, B ;
Jones, SA .
GENES & DEVELOPMENT, 2003, 17 (13) :1581-1591
[9]   Temporal and quantitative correlations between insulin secretion and stably elevated or oscillatory cytoplasmic Ca2+ in mouse pancreatic β-cells [J].
Jonas, JC ;
Gilon, P ;
Henquin, JC .
DIABETES, 1998, 47 (08) :1266-1273
[10]   Insulin resistance and pancreatic β cell failure [J].
Kasuga, Masato .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07) :1756-1760